局限性前列腺癌长期雄激素剥夺治疗后骨密度变化的临床意义
本研究基于III期随机试验PCS-V,分析接受28个月黄体生成素释放激素激动剂及钙和维生素D补充的局限性高危前列腺癌患者的骨密度变化。结果显示腰椎、股骨颈和全股骨骨密度平均下降,但多数患者临床骨密度分级未恶化,仅4%进展为骨质疏松。提示单纯钙和维生素D补充可能对多数患者足够。
要点
- 长期ADT期间骨密度轻度下降,但临床骨密度分级大多稳定。
- 钙和维生素D补充可能足以管理多数患者的骨健康。
- 仅4%患者进展为骨质疏松,骨折风险未评估。
核心结论
- 长期ADT导致骨密度轻度下降,但临床骨密度分级变化不大,钙和维生素D补充可能对多数局限性前列腺癌患者足够。
研究设计与样本
- 基于III期随机试验PCS-V的骨密度分析,纳入接受常规或大分割放疗的局限性高危前列腺癌患者。
- 患者接受28个月黄体生成素释放激素激动剂及钙(500 mg bid)和维生素D3(400 IU bid)补充。
- 分析基线及30个月随访时腰椎、股骨颈和全股骨的面积骨密度和T值,计算绝对变化。
主要发现
- 腰椎、股骨颈和全股骨骨密度平均百分比变化分别为-2.65%、-2.76%和-4.27%(所有p<0.001)。
- 所有部位平均骨密度下降-3.2%,但83%患者骨密度分级无下降。
- 8例患者(4%)进展为骨质疏松。
关键数值与推荐
- 腰椎、股骨颈和全股骨骨密度测量患者数分别为226、231和173例。
- 骨密度分级(正常、骨量减少、骨质疏松)在基线及30个月时评估。
临床怎么用
- 对于接受长期ADT的局限性前列腺癌患者,钙和维生素D补充可能足以维持骨健康,无需常规加用其他抗骨质疏松药物。
局限性
- 未评估骨折风险。
- 骨密度测量患者数各部位不同,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Long-term androgen deprivation therapy has been associated with decreased bone mineral density in men with prostate cancer. Some evidence suggests that there is no impact on fracture risk despite this bone mineral density loss. Our study aimed to quantify changes in bone mineral density in men with high risk prostate cancer on long-term androgen deprivation therapy and calcium and vitamin D supplementation. MATERIALS AND METHODS: Bone mineral density analysis was conducted for localized high risk prostate cancer patients enrolled in the phase III randomized trial PCS-V (Prostate Cancer Study 5), comparing conventional and hypofractionated radiation therapy. Patients received 28 months of luteinizing hormone-releasing hormone agonist and calcium and vitamin D supplementation (500 mg calcium BID+400 IU vitamin D3 BID). The areal density and T-scores (spine, femoral neck and total femur) at baseline and 30 months of followup were extracted, and the absolute change was calculated. Clinical bone density status (normal, osteopenia, osteoporosis) was monitored. RESULTS: The lumbar spine, femoral neck and total femoral bone mineral density were measured for 226, 231, and 173 patients, respectively. The mean percent change in bone mineral density was -2.65%, -2.76% and -4.27% for these respective sites (p <0.001 for all). The average decrease in bone mineral density across all sites was -3.2%, with no decline in bone mineral density category in most patients (83%). Eight patients (4%) became osteoporotic. CONCLUSIONS: Despite a mild decline in bone mineral density, the change in clinical bone mineral density category remained low with long-term androgen deprivation therapy. Consequently, calcium and vitamin D supplementation alone may suffice for most localized prostate cancer patients on long-term androgen deprivation therapy.
引用
- Khriguian J, Tsui JMG, Vaughan R, et al. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients. J Urol. 2021. PMID: 33577365. doi:10.1097/JU.0000000000001646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。